ClinicalTrials.gg
CompletedNCT00443170Updated Mar 19, 2012

A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

A Phase 1 interventional study of GSK626616, placebo, midazolam and omeprazole, caffeine, flurbiprofen, rosiglitazone in Healthy Subjects and Anaemia, sponsored by GlaxoSmithKline. Completed at 3 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-03-19.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Anemia by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Anemia · GlaxoSmithKline.

Enrollment
16th of 35
90 · median 72
Started
2006
the only one that year
Phase 1
14 of 35
none open now
Registered
1st of 35
by date

Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 16th largest by enrollment, is the only one that started in 2006, is one of 14 in phase 1, and was the 1st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 214 are open to participants now.

Browse Anemia studies →

Open to participants now

None of the 35 studies in Anemia by GlaxoSmithKline is open now. The open studies under Anemia, anywhere →

Who these studies take

Of the 121 Anemia studies recruiting now, 67 (55%) set no upper age limit and 36 (30%) stop at 75 or younger; 33 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Anemia by GlaxoSmithKline as a file.
02

Study summary

This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects. An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616.

03

Conditions studied

  • Healthy Subjects
  • Anaemia

Browse trials for

Keywords

  • repeat dose,
  • GSK626616AC,
  • pharmacokinetic,
  • single dose,
  • cytochrome P450,
  • First time in human,
  • healthy volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 55 years healthy subjects
  • values of 13.5-17.0 g/dL for males or 12.0-15.5 g/dL for females.
  • Females cannot be pregnant.

Exclusion criteria

Exclusion Criteria:

  • Cannot have exposure to greater than 4 new chemical entities within 12 months.
  • Cannot have a clinical history of current alcohol, or illicit drug use which, in the judgment of the Investigator, would interfere with the subject's ability to comply with the dosing schedule.
  • Cannot have a history of regular use of tobacco- or nicotine-containing products within 3 months.
  • Must not have received a blood transfusion or had a donation of blood within 3 months prior to study entry.
  • Cannot use be taking prescription, non-prescription or illicit drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single
Enrollment
90 participants (actual)

Interventions

  • DrugGSK626616, placebo, midazolam
  • Drugomeprazole, caffeine, flurbiprofen, rosiglitazone

    Drug pages: Omeprazole · Caffeine · Flurbiprofen · Rosiglitazone

    Also known as: omeprazole, caffeine, flurbiprofen, rosiglitazone, GSK626616, placebo, midazolam

06

What researchers measure

Primary outcomes

  1. adverse events at end of each cohort

    Time frame: end of each cohort

  2. hematology/chemistry/urinalysis at end of each cohort

    Time frame: end of each cohort

  3. physical examination at end of each cohort

    Time frame: end of each cohort

  4. vital signs and electrocardiogram (ECG) at end of each cohort

    Time frame: end of each cohort

Secondary outcomes

  1. GSK626616 pharmacokinetics at end of each cohort

    Time frame: end of each cohort

  2. hemoglobin at end of each cohort

    Time frame: end of each cohort

  3. red blood cell measurements at end of each cohort

    Time frame: end of each cohort

  4. estimates of CYP enzyme activity at end of study

    Time frame: end of study

  5. mRNA levels in peripheral blood at end of study

    Time frame: end of study

07

Study locations

3 sites
  • GSK Investigational Site
    Randwick, Sydney, New South Wales 2031, Australia
  • GSK Investigational Site
    Herston, Queensland 4006, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00443170
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 5, 2007
Start date
Nov 2006
Last update
Mar 19, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omeprazole · Caffeine · Flurbiprofen · Rosiglitazone

Start the discussion